News NEJM responds to claims of bias from Justice Department The New England Journal of Medicine (NEJM) has hit back at assertions of bias in its editorial policies from Republican activist Edward Martin Jr.
News Eisai's full lecanemab phase 3 trial results for Alzheimer's... Following the news of two lecanemab-related deaths reported on the eve of the C
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.